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Background: The BRAFV600E mutation is the most common genetic alteration in papillary thyroid carcinomas
(PTCs). Transgenic mice overexpressing BRAFV600E in their thyroids under control of the thyroglobulin promoter
(Tg-BRAF2 mice) developed invasive PTCs with high penetrance. However, these mice showed elevated thy-
rotropin (TSH) levels, which also stimulate the proliferation of thyrocytes and tumorigenesis. The purpose of the
present study was to investigate how TSH signaling cooperates with BRAFV600E in the process of thyroid
carcinogenesis.
Methods:We crossed Tg-BRAF2mice with TSH receptor knockout (TshR - /- ) mice. Four genetically distinct mice
groups—Brafwt/TshR +/ - (group 1), Brafwt/TshR -/ - (group 2), Tg-BRAF2/TshR +/ - (group 3), and Tg-BRAF2/
TshR -/- (group 4)—were sacrificed at 12 and 24 weeks of age. We performed histopathological analysis.
Genomic instability was evaluated by immunofluorescence for p53-binding protein 1 (53BP1) and cH2AX.
Invasiveness and genomic instability were also evaluated using thyroid PCCL3 cells expressing BRAFV600E.
Results: Groups 3 and 4 developed distinct neoplasias comparable to human PTCs. Group 3 developed typically
larger, more aggressive, invasive tumors compared to group 4. The frequency of 53BP1 and cH2AX foci—
indicators of genomic instability—in group 3 was higher than that in group 4. TSH also enhanced invasiveness
and genomic instability in PCCL3 cells with BRAFV600E expression.
Conclusions: These data demonstrate that the TSH signaling confers more aggressive features in BRAFV600E-
induced thyroid tumors in mice. This might be due, in part, to accelerated genomic instability.
Introduction
Papillary thyroid cancer (PTC) represents the mostfrequently occurring type of differentiated thyroid cancer
(1). PTCs are associated with characteristic genetic alterations
including RET/PTC rearrangements and activating point
mutations involving BRAF and the RAS family genes. These
mutually exclusive gene mutations typically result in activa-
tion of the MAPK signaling pathway, thus providing strong
genetic evidence that constitutive activation of this cascade is
critical to the transformation of thyrocytes to PTC (2–4).
The BRAF activating mutation is the most common ge-
netic aberration in PTCs (29–83%) (5). It is most commonly
due to a thymine-to-adenine transversion at nucleotide1799
(c.1799T >A), resulting in a valine-to-glutamic acid substitu-
tion at amino acid 600 (p.V600E). It is believed that this mu-
tation destabilizes the interactions that maintain the DFG
motif in an inactive conformation, and that the mutation flips
the activation segment into the active position (6). Therefore,
BRAFV600E constitutively activates the MAPK pathway and is
thought to play a major role in PTC tumorigenesis (7,8).
Although the majority of PTCs have an excellent out-
come with treatment (9), several studies have shown that the
BRAFV600E mutation in PTC is associated with aggressive
clinicopathological features such as advanced clinical stage,
extrathyroidal extension, and lymph-node metastasis (7).
These tumors also have a high risk of recurrence (10). Trans-
genic mice overexpressing BRAFV600E in thyrocytes under
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control of the thyroglobulin (Tg) gene promoter developed
PTC with distinct tall cells and poorly differentiated areas
(11), which are aggressive features of human PTCs. However,
thesemicewere severely hypothyroidwith consequently high
thyrotropin (TSH) levels because the function of all thyrocytes
was impaired by the expression of the oncoprotein. In ro-
dents, it is known that increasing serum TSH by prolonged
administration of an antithyroid drug leads to development of
thyroid cancer, albeit at low penetrance (12). Most thyroid
cancer mouse models similarly show elevated TSH levels
because of this hormonal feedback system. However, the role
of the high TSH levels in these mouse models remains less
clear.
So far, two mouse models have been developed to study
the role of TSH in thyroid carcinogenesis. Lu et al. crossed
TRbPV/PV mice—a model of follicular thyroid cancer—with
TSH receptor (TSHR) knockout mice (13). Surprisingly, the
tumorigenic effect of TRbPV/PV was totally abolished in the
TRbPV/PV/TshR -/ - mice. Only a few, small-sized follicles (no
tumors) were observed in their thyroids. Recently, Franco
et al. established anothermousemodel (14). They crossedmice
with a thyroid-specific knock-in of BrafV600E (LSL-BrafV600E/
TPO-Cre) with TshR -/ - mice. By three weeks (at this time
point, thyroid cancer was seen in LSL-BrafV600E/TPO-Cre
mice), they developed benign tumors without characteristic
nuclear features of human PTCs. However, by nine weeks,
they progressed to low-grade PTCs.
Genomic instability (GIN) is a hallmark of cancers and has
been suggested to play a crucial role in the progression of
thyroid tumors (15,16). p53-binding protein 1 (53BP1) is a
DNA damage response protein that rapidly localizes at the
site of DNA double-strand breaks (DSB) together with phos-
phorylated ATM and many other related proteins such as
cH2AX (17–20). One of the manifestations of GIN is the in-
duction of DSB, and it has been demonstrated that 53BP1
focus formation can be used as a marker of GIN (16,21). Ad-
vanced and more malignant thyroid cancer tissues showed
intense and abnormal nuclear 53BP1 staining patterns com-
pared with low-grade cancers, suggesting increased GIN in
advanced cancer cells.
To examine the role of TSH signaling in thyroid carcino-
genesis in vivo, we developed mice with thyrocyte-targeted
BRAFV600E expression crossed with the TshR gene knockout
mice. We also evaluated cell proliferation and GIN status in
their thyroids, and demonstrate that TSH signaling may be




The PC-BRAFV600E-6 line was derived from PCCL3 cells, a
clonal rat thyroid cell line, to obtain doxycycline-inducible
BRAFV600E expression as previously described (22). The cells
were maintained in H4 complete medium consisting of
Coon’s F-12 medium (Sigma) supplemented with 5% tetra-
cycline screened fetal bovine serum (FBS;Hyclone), 0.3mg/mL
l-glutamine, 1 mIU/mL TSH, 10 lg/mL insulin, 5 lg/mL
apo-transferrin, 10 nM hydrocortisone, and penicillin/strep-
tomycin. H3 medium contained the same constituents ex-
cept for TSH. To induce BRAFV600E expression, the cells were
treated with 1lg/mL of doxycycline.
Mice
FVB/N, bovine Tg promoter-driven BRAFV600E transgenic
mice—Tg-BRAF2 mice (11)—were obtained from Dr. James
Fagin (University of Cincinnati; currently Memorial Sloan-
Kettering Cancer Center). C57/Bl6J-129 hybrids—thyrotropin
receptor null mice (TshR -/ - ) (23)—were obtained from
Jackson Laboratory Inc. Both strains were crossed, and off-
spring were genotyped using tail DNA as described previ-
ously (11,23). All the mice were bred in a specific pathogen-
free facility. Mice with TshR-/- were fed with a desiccated
thyroid powder (100 ppm)-supplemented diet (23). Animal
care and all experimental procedures were performed in ac-
cordance with the Guidelines for Animal Experimentation of
Nagasaki University with the approval of the Institutional
Animal Care and Use Committee.
Thyroid weight and histology
Mice were sacrificed at 12 and 24 weeks of age. Thyroid
glands were removed, weighed, and frozen in liquid nitrogen
for real-time reverse-transcription PCR (RT-PCR) described
below. Formalin-fixed and paraffin-embedded (FFPE) thyroid
tissue sections were stained with hematoxylin and eosin
(H&E) for histology and pathological scoring of lesions. Ag-
gressiveness of the tumor tissueswas scored based on the sum
of the following parameters: invasion, yes = 1 or no= 0; solid
pattern, ‡ 40% = 1 or < 40% = 0.
Real-time quantitative RT-PCR
Total RNA was isolated from homogenized thyroid tissues
using ISOGEN reagent (Nippon Gene). Two hundred nano-
grams of the total RNA was reverse transcribed with High
Capacity RNA-to-cDNA Kit (Applied Biosystems) in the
presence of random hexamers to generate cDNA. The fol-
lowing quantitative PCR was carried out in a Thermal Cycler
Dice Real-time system (TaKaRa Bio) using QuantiTect SYBR
Green PCR Kit (Qiagen). The sequences of used primer pairs
were described previously (11). The cycle threshold value,
which was determined using second derivative, was used to
calculate the normalized expression of the indicated mRNAs
with Q-Gene software (24) using b-actin for normalization.
Immunohistochemistry
For cleaved caspase-3 detection, FFPE sections were de-
paraffinized and subjected to antigen retrieval by microwave
treatment in citrate buffer. After blocking, the sections were
incubated with anticleaved caspase-3 antibody #9661 (1:250
dilution; Cell Signaling Technology) overnight at 4C. Stain-
ing was performed using the Vectastain Elite ABC Kit (Vector
Laboratories) and 3,3¢-diaminobenzidine (DAB). For F4/80
staining, FFPE sections were deparaffinized and treated with
proteinase K. After blocking, the sections were incubated
with anti-mouse F4/80 antibody Cl:A3-1 (1:50 dilution; AbD
Serotec) overnight at 4C followed by incubation with HRP-
conjugated anti-rat IgG secondary antibody (Dako). Visuali-
zation was done with DAB.
Immunofluorescence
FFPE sections were deparaffinized and subjected to antigen
retrieval bymicrowave treatment in citrate buffer. For 53BP1/
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Ki67 co-staining, the tissues were then incubated with a
mixture of rabbit anti-53BP1 antibody A300-272A (1:200 di-
lution; Bethyl Laboratories Inc.) and rat monoclonal anti-
mouse Ki67 antibody Clone TEC 3 (1:50 dilution; Dako) in 5%
milk in TBS-T buffer. After two hours of incubation at room
temperature, the tissues were incubated with another mixture
of Alexa Fluor 532-conjugated goat anti-rabbit and Alexa
Fluor 647-conjugated goat anti-rat antibodies (Invitrogen).
For cH2AX staining, anti-phosphorylated H2AX (Ser139)
Clone 2F3 (1:500 dilution; BioLegend) and Alexa Fluor 488-
conjugated anti-mouse antibody (Invitrogen) were used.
After counterstaining with 4¢,6-diamidino-2-phenylindole
(DAPI), images were visualized and captured using a fluo-
rescence microscope (Leica DM 6000B). Immunoreactivity
signals were analyzed at 400· magnification in four to six
fields of view per sample, and analyzed with the NIH Image J
toolkit (http://rsbweb.nih.gov/ij/index.html).
For detection of cH2AX in PC-BRAFV600E cells, the cells
were grown on coverslips and pretreatedwithH3medium for
seven days. The medium was then replaced by H3 or H4
medium with or without doxycycline. After incubation for 24
hours, the cells were fixed with 10% formalin and permeabi-
lized with 0.5% Triton-X in PBS. Anti-phosphorylated H2AX
(Ser139) antibody Clone JBW301 (1:1000 dilution, Millipore)
was used as a primary antibody. After labeling with a sec-
ondary antibody conjugated with Alexa Fluor 488, images
were acquired using a fluorescence microscope.
Matrigel invasion assay
The Matrigel invasion assay was performed in triplicate
using the PC-BRAFV600E-6 cells. Matrigel (BD Biosciences;
60 lg/transwell) diluted with serum-free mediumwas placed
on 24-well format transwell cell culture inserts (Corning; 8-lm
pore size). After seven days of TSH starvation in H3 medium,
the cells were resuspended in 200lL serum-free mediumwith
and without doxycycline in the presence or absence of TSH
and added to the upper chamber at 8 · 104 cells per insert.
Next, 750 lL complete medium with 10% FBS was added to
the lower chamber of each transwell. After 24 hours’ incuba-
tion, nonmigrated cells at the upper side of the membrane
were mechanically removed with cotton swabs, and the
transwells were washed with PBS, fixed with 100%methanol,
and stained with Giemsa Stain solution (Sigma). Cells that
invaded the Matrigel and migrated to the lower side of the
membrane were quantified in 10 random images per trans-
well taken at 10· magnification in a bright field microscope.
The number of migrated cells were counted using the NIH
Image J toolkit.
Statistical analysis
Differences between groups were examined for statistical
significance by unpaired t-test or analysis of variance (AN-
OVA) followed by Tukey’s post-hoc test. A p-value < 0.05 was
considered statistically significant.
Results
BRAFV600E generates tumors in mice,
and TSH increases tumor size
We first crossed Tg-BRAF2 mice with TshR -/- mice to
obtain Tg-BRAF2/TshR +/ - mice, and then the Tg-BRAF2/
TshR +/- mice were further crossed with TshR -/- mice.
Offspring were genotyped and divided into four groups:
Brafwt/TshR +/ - (group 1), Brafwt/TshR -/ - (group 2),
Tg-BRAF2/TshR+/- (group 3), and Tg-BRAF2/TshR -/ -
(group 4). Although previous reports demonstrated Tg ex-
pression in the thyroids of TshR-/- mice (23,25), we assessed
BRAFV600E expression by real-time RT-PCR because the Tg
promoter activity is dependent on TSH stimulation in vitro, and
the bovine Tg promoter drove the expression of BRAFV600E in
our model. In the thyroid lobes collected at 12 weeks, the
BRAFV600E expression levels in the group 3 mice were com-
parable to those in group 4 (Fig. 1), indicating that BRAFV600E
was properly transcribed regardless of TSH signaling. We also
examined other thyroid-specific genes, the sodium-
iodide symporter (Nis) and Tg.Nis expression was remarkably
downregulated in TshR-/- mice (groups 2 and 4; Fig. 1). Re-
garding Tg, its expression in group 3 was also reduced, as well
as in groups 2 and 4 (Fig. 1), suggesting that the dediffer-
entiating effect of BRAFV600E on the expression of Tg was
strong.
The ratio of thyroid weight to body weight was compared
among the four groups at both 12 and 24 weeks. Note that
body weights of group 2 and group 4 mice (TshR -/ - ) at five
weeks were smaller than those of group 1 and group 3 mice
(TshR+/- ), presumably due to hypothyroidism. However,
these differences were diminished until 12 weeks (following a
thyroid powder-supplemented diet beginning at four weeks
FIG. 1. Effect of TshR knockout on mRNA
levels of transgene and thyroid-specific
genes. Total RNA was extracted from the
thyroids at 12 weeks and subjected to quan-
titative reverse-transcription polymerase
chain reastion (qRT-PCR) for the expression
of the indicated genes after normalization to
b-actin. Columns represent means and stan-
dard error of the mean (SEM) of values ob-
tained from three independent biological
replicates. 1, group 1 (Brafwt/TshR +/ - ); 2,
group 2 (Brafwt/TshR -/ - ); 3, group 3
(Tg-BRAF2/TshR +/ - ); 4, group 4
(Tg-BRAF2/TshR -/ - ).
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(Supplementary Fig. S1; Supplementary Data are available
online at www.liebertpub.com/thy). The ratio of thyroid
weight to body weight was the highest in group 3 (Fig. 2A).
However, there was no significant difference between groups
1, 2, and 4 (Fig. 2A). These data demonstrate the obvious
influence of TSH signaling on BRAFV600E-induced goiter for-
mation. Representative low-power images of thyroid sections
in each group are shown in Figure 2B. Group 1 showed a
normal structure (Fig. 2B). The thyroids in group 2 had fewer
follicles and some adipose tissue (Fig. 2B). In group 3, the
thyroid glands were markedly enlarged, and no normal fol-
licles were observed (Fig. 2B). These data are consistent with
previous reports (11,23). In group 4 mice with BRAFV600E
without TSH signaling, the normal follicular architecture was
also completely disrupted, and their morphology was similar
to that in group 3 (Fig. 2B). However, the size of the glands
was much smaller (Fig. 2B), which is in accordance with their
lower weights (Fig. 2A). No metastasis was found in either
group 3 or group 4.
TSH signaling confers more aggressive features
in BRAFV600E-induced thyroid tumors
Next, we performedmicroscopic analyses of groups 3 and 4
using H&E stained sections. Figure 3 shows representative
findings of BRAFV600E-induced tumors in the group 3 mice.
The mice developed neoplastic lesions distorting the entire
thyroid glands (Fig. 3A). Solid pattern (Fig. 3C), capsular in-
vasion (Fig. 3D), and tall cells lining papillary structures (Fig.
3E) were observed, and these features were similar to human
aggressive PTCs. Papillary projection (Fig. 3B) and nuclear
clearing (Fig. 3F) were also observed.
Most of the mice in both groups developed neoplasias with
features characteristic of human PTC, including nuclear
changes such as nuclear clearing, grooves, and inclusions
FIG. 2. Effect of TSH sig-
naling on BRAFV600E-induced
thyroid tumor formation. (A)
Dot plots represent individ-
ual values and means (bars)
of ratio of thyroid lobe
weights (mg) to body weights
(g) at sacrifice. (B) Re-
presentative hematoxylin and
eosin (H&E) stained sections
of thyroid lobes at 24 weeks.
*p< 0.05.
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(Table 1). Tall cells, which are thought to be an aggressive
subtype, were also seen in 7/20 and 8/19 mice in group 3 and
group 4 respectively (Table 1). By contrast, a solid pattern,
which is another aggressive feature in PTC, was observed
more frequently in group 3 (6/20) than in group 4 (3/19; Table
1). Capsular invasion was only observed in group 3 (5/20),
while group 4 showed no features suggestive of capsular in-
vasion or extrathyroidal extension (Table 1). A papillary
pattern was more common in group 4 (data not shown).
A time-dependent trendwas observed, particularly in group 4
where the papillary pattern at 12 weeks was replaced by solid
features at 24 weeks (Table 1; data not shown). We carried out
histopathological scoring of the neoplastic lesions in groups 3
and 4. The aggressiveness score for group 3 (0.550 – 0.170)was
higher than that of group 4 (0.158– 0.086), which was statis-
tically significant ( p= 0.0498, unpaired t-test). These data
suggest that TSH signaling results in a more aggressive phe-
notype in the BRAFV600E-induced thyroid tumors.
FIG. 3. Representative im-
ages of H&E stained sections
from thyroid tissues of group
3 (Tg-BRAF2/TshR +/- ) mice:
(A) low power view (· 100)
of the thyroid neoplasm; (B)
intrafollicular papillary pro-
jection ( · 200); (C) solid pat-
tern replacing normal thyroid
architecture ( · 100); (D) ex-
tracapsular extension (arrows
depict remnant of the capsule
[R; · 200]); (E) tall cells
(T; · 400); (F) nuclear clearing
( · 400).
Table 1. Histopathological Scoring of Thyroid Lesions in BRAFV600E/TshR +/ - and BRAFV600E/TshR -/ - Mice
Overall process Cellular features









BRAFV600E/TshR +/ - 12 9/10 9/10 3/10 2/10 2/10
24 10/10 9/10 4/10 4/10 3/10
BRAFV600E/TshR -/ - 12 8/9 7/9 3/9 0/9 0/9
24 9/10 8/10 5/10 3/10 0/10
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TSH prevents apoptosis but not macrophage
infiltration
To examine the influence of apoptosis on the difference
between groups 3 and 4, we performed immunohistochem-
istry for cleaved caspase-3. The percentage of positively
stained cells was significantly higher in group 4 than in group
3 at 12weeks (Fig. 4A). Therewas also a similar tendency at 24
weeks, but no statistical significance was observed (Fig. 4A).
These results suggest that the TSH signal has a role in pre-
venting apoptosis, and this may cause, at least in part, the
difference in thyroid size between groups 3 and 4.
Recently, it has been demonstrated that tumor-associated
macrophages have a role in the progression of BRAFV600E-
induced thyroid cancer, particularly PTC, to poorly differen-
tiated thyroid carcinoma (26). To test this possibility, we also
performed immunohistochemistry for F4/80. As shown in
Fig. 4B, however, there was no difference between groups 3
and 4.
TSH enhances BRAFV600E-induced
cell invasiveness in rat thyroid cells
To support the in vivo observation,weutilized a doxycycline-
inducible BRAFV600E rat thyroid cell line—PC-BRAFV600E-6
cells (22)—and performed a cell invasion assay in vitro. As
shown in Fig. 5, BRAFV600E expression (treatment with doxy-
cycline) robustly enhanced cell invasiveness in the presence of
TSH (4H). However, deprivation of TSH (3H) significantly
suppressed the invasive ability. These data also demonstrate
that BRAFV600E and TSH cooperatively induce invasiveness in
thyroid cells.
TSH signaling induces GIN
To explore the influence of TSH signaling and BRAFV600E
on tumor growth and induction of aggressive features, we
performed dual-label immunofluorescence for 53BP1 and
Ki67. Representative merged images of each group are pre-
sented in Fig. 6A. The percentage of 53BP1 focus-positive and
Ki67-positive cells was calculated. Regarding the comparison
between group 3 and 4, the frequency of 53BP1 focus-positive
cells in group 3was significantly higher than that in group 4 in
24-weekmale and 12-weekmalemice (Fig. 6B). The frequency
in 24-week female mice in group 3 also showed a higher trend
compared to group 4. However, it did not reach statistical
significance (Fig. 6B). Notably, the group 1mice also exhibited
higher percentages at 24 weeks, and the frequencies in female
mice were generally higher than those in male mice (Fig. 6B).
Regarding the proliferative index, Ki67 positivity in the group
1 and 2 mice was very low (Fig. 6B). By contrast, in groups 3
and 4, BRAFV600E robustly increased the Ki67-positive cells
(Fig. 6B). However, there was no statistical difference between
groups 3 and 4 (Fig. 6B). To confirm the above observations
regarding GIN, we also used another DNA damagemarker—
cH2AX (phosphorylated H2AX at Ser-139). The frequency of
cH2AX foci in group 3 was significantly higher than that in
group 4 in all age/sex pairs (Fig. 6C). Similar findings were
also obtained in vitro using the PC-BRAFV600E-6 cells (Fig. 6D).
Discussion
In the present study, we show that TSH signaling confers
more aggressive features in BRAFV600E-induced thyroid tu-
mors in vivo. We utilized the Tg-BRAF2 mice in which the Tg
gene promoter drives BRAFV600E expression in thyroid fol-
licular cells (11). Even though Tg expression was highly
suppressed in group 3 and group 4 mice thyroids, BRAFV600E
expression was still maintained in both groups. This might be
due to a lack of distant regulatory element(s) or particularities
of the integration site of the transgene in this animal model.
Comparedwith the first report of the Tg-BRAF2mice (11), our
group 3 mice (Tg-BRAF2/TshR +/ - ) showed weaker pheno-
types: a lower percentage of tall cells (79–87% in (11) vs.
FIG. 4. Evaluation of apoptosis and mac-
rophage infiltration. Immunostaining was
performed using cleaved caspase-3 (A) and
F4/80 (B) antibodies. Each dot represents the
percentage of indicated positive cells relative
to *500 cells in four to six fields of view
counted under bright field microscopy.
Horizontal bars indicate means. *p < 0.05.
FIG. 5. Effect of TSH and/or BRAFV600E on cell invasion.
Invasion was examined using Matrigel and Transwell cham-
bers. After TSH starvation for seven days, PC-BRAFV600E-6
cells were treated with or without doxycycline in the presence
or absence of thyrotropin (TSH) for 24 hours, and subjected to
Matrigel invasion assay. Each bar indicates mean and SEM of
three wells. *p< 0.05. Similar results were obtained in two
independent experiments.
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30–40% in group 3) and capsular invasion (73–93% in (11) vs.
20–30% in group 3). This is presumably due to hemizygosity
of the TshR and consistent with the report by Franco et al.
demonstrating that thyroid weights in LSL-BrafV600E/TPO-
Cre/TshR +/ - mice were approximately half of those in LSL-
BrafV600E/TPO-Cre mice (14). Although growth, histology,
and serum T3/T4/TSH levels were all normal in the TshR +/ -
mice (23), the influence of difference in TSH signal between
wild type and TshR +/ - on thyroid tumor formation is prob-
ably significant, especially with elevated serum TSH levels.
These findings also suggest that TSH signaling plays an im-
portant role in BRAFV600E-induced thyroid tumorigenesis.
Although our current study and the report by Franco et al.
(14) used similar mouse models (Tg-BRAF2 and LSL-
BrafV600E/TPO-Cre respectively), there are some differences.
First, Ii our model, BRAFV600E expression was supposedly
induced from embryonic day 15, while in themodel by Franco
et al., the recombination of LSL-BrafV600E was gradually in-
duced and completed until 7–10 days postnatally. Second,
although our group 4 (Tg-BRAF2/TshR -/ - ) mice had some
characteristics of human PTC such as tall cells and nuclear
features at both 12 and 24weeks, the LSL-BrafV600E/TPO-Cre/
TshR -/- mice by Franco et al. did not show any nuclear fea-
tures of human PTC at three weeks and no tall cells even at
nine weeks. This difference might be due to the time of onset
of the expression of the oncoprotein. Prolonged expression
beginning at the embryonic stage may induce characteristic
features of human PTC even in the absence of TSH signaling.
Despite some differences, however, our overall results are
quite consistent with the study by Franco et al. (14).
We analyzed GIN using immunofluorescence for 53BP1.
Interestingly, 53BP1 foci formation in the group 1 mice was
increased in a time-dependent manner (12 and 24weeks) even
though proliferation of thyrocytes (Ki67) was absent, sug-
gesting that the foci were not caused by TSH-mediated DNA
replication. SinceNis and thyroid peroxidase (Tpo) expression
(but not Tg) was highly suppressed [(25) and our data] inmice
with TshR-/ - , oxidative stress by iodide and/or Tpo during
thyroid hormonogenesis may be responsible for DSB forma-
tion. However, further research is needed to confirm this
FIG. 6. Evaluation of genomic instability and cell proliferative activity. (A) Representative images of immunofluorescence of
the thyroid tissues obtained from indicated groups. White and yellow arrowheads indicate Ki67 positive cells (green) and
53BP1 foci (red) respectively. Nuclei were stained with DAPI (blue). (B) Dot plot analysis of 53BP1 foci and Ki67 in
thyrocytes. Each data point represents a single subject and depicts the percentage of cells having 53BP1 foci or Ki67 at 12 and
24 weeks. In each point, at least 2000 cells were analyzed. Horizontal bars indicate means; p-values generated by analysis of
variance (ANOVA) and post-test values are also provided. (C) Dot plot analysis of cH2AX foci. In each point, at least 2000
cells were analyzed. Horizontal bars indicate means. *p< 0.05 by unpaired t-test. (D) cH2AX staining in PC-BRAFV600E-6 cells.
After TSH starvation for seven days, the cells were treated with or without doxycycline in the presence or absence of TSH for
24 hours, and subjected to immunofluorescence for cH2AX. Each bar indicates mean and SEM of three wells. *p < 0.05 by
ANOVA and post-test. Color images available online at www.liebertpub.com/thy
508 ORIM ET AL.
connection. On the other hand, in BRAFV600E-induced thyroid
tumor cells, the frequency of 53BP1 foci in group 3 was also
higher than that in group 4. Since the 53BP1 frequency in
group 1 was lower than that in group 3 in 12-week-old mice,
BRAFV600E (22) and TSH signaling may cooperatively induce
GIN in thyrocytes. Our experiments showing an increased
number of cH2AX foci strongly support this notion.
Our data in the present study suggest that the activity of the
TSH signaling pathway confers more aggressive features in
BRAFV600E-induced thyroid tumors in vivo. This might be due,
in part, to accelerated genomic instability. Generally, these
results suggest that TSH signaling plays an important role in
tumor progression rather than tumor initiation in our model.
Since several epidemiological studies have accumulated evi-
dence of an association between serum TSH levels and risk of
malignancy in patients with thyroid nodules (27–30), the
current study may provide additional insight in terms of
prevention of this type of cancer.
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